TScan Therapeutics, Inc.’s TCRX share price has surged by 9.62%, which has investors questioning if this is right time to sell.

Coherus BioSciences, Inc.’s CHRS share price has dipped by 5.19%, which has investors questioning if this is right time to ...

Novartis' Vanrafia reduced proteinuria by 36.1% in IgAN patients using a RAS inhibitor. Continued FDA approval depends on Phase 3 ALIGN study results in 2026. Feel unsure about the market’s next ...

The approval is the third in the US for of Novartis’ kidney disease portfolio. Credit: Taljat David/Shutterstock. The US Food and Drug Administration (FDA) has granted accelerated approval to Novartis ...

Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for Biomedical Research. Prior to joining Novartis, Dr. Sellers was an ...

It was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with UK biotech, Astex Pharmaceuticals.

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

Deborah Fuller receives funding from the National Institutes Health. The personal views expressed here are those of the authors. Patrick Mitchell receives funding from the National Institutes of ...

It’s a significant blow to Whitman-Walker's research institute’s budget — and real estate plans. The National Institutes of Health has rescinded $1.4 million of a $2 million grant to Whitman ...

Jay Bhattacharya, who is an Indian-origin professor at Stanford School of Medicine, is confirmed as the Director of NIH. Bhattacharya had earlier faced questions about his plans for vaccine research, ...

SOUTH KINGSTOWN, R.I. — The email came by complete surprise on Friday afternoon, chemical engineering professor Samantha Meenach said. The research program she runs at the University of Rhode ...